Stock within Traders Limelight: Teva Pharmaceutical Industries Limited (TEVA)

EPS growth in next year is estimated to reach -1.78% while EPS growth estimate for this year is set at -96.10%. Annual earnings per share (EPS) growth was at -53.00% in past 5 Years and Long-term annual earnings per share (EPS) growth is projected to achieve 2.83% in coming 5 years. The firm has "Outperform" rating by Wells Fargo given on Friday, February 19.

In Drug Manufacturers - Other Industry, Teva Pharmaceutical Industries Limited (TEVA) have 1.03 billion outstanding shares now held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders. The company beat the analyst EPS Estimate with the difference of $0.05. Agran Libbie sold 9,415 shares as Teva Pharmaceutical Inds Ltd (TEVA)'s stock declined 15.11%. It has a return on equity (ROE) of 0.30%.

The High Revenue estimate is predicted as 6.01 Million, while the Low Revenue Estimate prediction stands at 5.58 Million. During the same quarter in the prior year, the firm posted $1.20 earnings per share. Teva Pharmaceutical Industries's quarterly revenue was up 17.0% on a year-over-year basis.

Research analysts are predicting that, Inc. The hedge fund run by Matthew Mark held 449,200 shares of the medical specialities company at the end of 2016Q4, valued at $55.71M, up from 245,200 at the end of the previous reported quarter. JP Morgan reinitiated Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) on Monday, August 3 with "Overweight" rating.

Analyst recommendation for this stock stands at 2.50. As per Monday, December 7, the company rating was initiated by Mizuho. At recent closing price of $29.53, TEVA has a chance to add $7.33 or 24.82% in 52 weeks, based on mean target price ($36.86) placed by analysts.The analyst consensus opinion of 2.5 looks like a hold.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by Stock Observer and is the sole property of of Stock Observer. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and global copyright law. The original version of this news story can be accessed at Jet Capital Investors LP who had been investing in Aetna Inc New (Call) for a number of months, seems to be bullish on the $49.74 billion market cap company. Franklin Resources Inc. increased its stake in Teva Pharmaceutical Industries by 20.9% in the fourth quarter. Finally, Financial Architects Inc raised its position in shares of Teva Pharmaceutical Industries by 2.3% in the first quarter. Highfields Capital Management LP increased its stake in Teva Pharmaceutical Industries by 106.2% in the fourth quarter. Bank Hapoalim BM now owns 11,673 shares of the company's stock worth $375,000 after buying an additional 980 shares during the period. Vetr lowered Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating and set a $40.48 target price on the a research report on Thursday, February 16th. Its down 3.42% from 8.08 million shares previously. During the last month, the stock has changed 5.39% and performed -13.83% over the last 6 months. By reviewing stock prices from the stock market history of the company and examining its analysts ratings can give an investment picture with updated information of stock which helps investors to make investing decision. The firm's 50-day moving average is $30.30 and its 200 day moving average is $33.52. Teva Pharmaceutical Industries has a 52 week low of $27.60 and a 52 week high of $56.44.

Given the importance of identifying companies that will grow earnings per share at high rate, we then need to consider how to identify which companies will achieve high growth rates. Investors of record on Monday, June 5th will be issued a dividend of $0.34 per share. The ex-dividend date is Thursday, June 1st.

  • Zachary Reyes